Dyne Therapeutics/$DYN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Ticker
$DYN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
192
ISIN
US26818M1080
Website
DYN Metrics
BasicAdvanced
$1.2B
-
-$3.62
1.19
-
Price and volume
Market cap
$1.2B
Beta
1.19
52-week high
$47.45
52-week low
$6.36
Average daily volume
2.7M
Financial strength
Current ratio
20.35
Quick ratio
19.996
Long term debt to equity
2.723
Total debt to equity
3.487
Profitability
EBITDA (TTM)
-395.312
Management effectiveness
Return on assets (TTM)
-39.92%
Return on equity (TTM)
-64.01%
Valuation
Price to book
1.83
Price to tangible book (TTM)
1.83
Price to free cash flow (TTM)
-3.384
Free cash flow yield (TTM)
-29.55%
Free cash flow per share (TTM)
-318.56%
Growth
Earnings per share change (TTM)
-7.32%
3-year earnings per share growth (CAGR)
5.22%
What the Analysts think about DYN
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
Bulls say / Bears say
U.S. Health Secretary Robert F. Kennedy Jr. announced plans to accelerate the approval of treatments for rare diseases, potentially benefiting companies like Dyne Therapeutics that focus on such conditions. (reuters.com)
Dyne Therapeutics' DYNE-251 demonstrated a mean absolute dystrophin expression of 3.71% of normal in a Phase 1/2 trial for Duchenne muscular dystrophy, exceeding levels typically recorded in studies evaluating other investigational oligomers for DMD. (benzinga.com)
Analysts have set an average price target of $47.46 for Dyne Therapeutics, indicating potential upside from its current trading price. (etfdailynews.com)
Dyne Therapeutics reported a quarterly adjusted loss of $1.05 per share for the quarter ended March 31, missing analysts' expectations of a loss of 88 cents per share. (tradingview.com)
The company conducted an upsized $300 million stock offering, which can dilute existing shareholders' value. (tradingview.com)
Dyne Therapeutics' stock price declined by 6.4% following an analyst downgrade, reflecting potential concerns about the company's prospects. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
DYN Financial Performance
Revenues and expenses
DYN Earnings Performance
Company profitability
DYN News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
GlobeNewsWire·2 days ago
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN
Business Wire·3 days ago
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dyne Therapeutics stock?
Dyne Therapeutics (DYN) has a market cap of $1.2B as of June 20, 2025.
What is the P/E ratio for Dyne Therapeutics stock?
The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of June 20, 2025.
Does Dyne Therapeutics stock pay dividends?
No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Dyne Therapeutics dividend payment date?
Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.
What is the beta indicator for Dyne Therapeutics?
Dyne Therapeutics (DYN) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.